Search Within

Linda Su Hyun Ahn

Formats
  1. Journal Article (13)
  2. Meeting Abstract (11)
  3. Review (1)
Groups
  1. Nursing (25)
  2. Department of Medicine (23)
  3. Solid Tumor Oncology Division (23)
  4. GSK Faculty (19)
  5. Thoracic Oncology (19)
  6. Radiology, Department of (17)

More Groups

People
  1. Mark Kris (12)
  2. Charles Rudin (10)
  3. Paul Paik (10)
  4. Helena Yu (9)
  5. Gregory Riely (8)
  6. Andrew Plodkowski (7)

More People

Years
  1. 2024 (2)
  2. 2023 (2)
  3. 2022 (3)
  4. 2021 (2)
  5. 2020 (3)
  6. 2019 (4)

More Years

Publications
  1. Journal of Clinical Oncology (8)
  2. Clinical Cancer Research (3)
  3. Journal of Thoracic Oncology (3)
  4. Cancer (2)
  5. Clinical Journal of Oncology Nursing (1)
  6. Cold Spring Harbor Molecular Case Studies (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (9)
  2. American Association for Cancer Research (3)
  3. Elsevier Inc. (3)
  4. Oncology Nursing Society (ONS) (2)
  5. Wiley Blackwell (2)
  6. American Medical Association (1)

More Publishers

Results (25)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease
    Meeting Abstract

    Yu, H. A.; Chen, M. F.; Hui, A. B.; Choudhury, N. J.; Lee, J. J. K.; Zheng, J.; Ahn, L. S. H.; Pupo, A.; Nesselbush, M.; Jabara, I.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Osimertinib, platinum, etoposide as initial treatment for patients with EGFR mutant lung cancers with TP53 and RB1 alterations
    Meeting Abstract

    Chen, M. F.; Rakhade, S.; Quintanal-Villalonga, A.; Lee, J.; Forsythe, B.; Moses, K. A.; Ahn, L. S. H.; Pupo, A.; Falcon, C. J.; Rekhtman, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228
    Journal Article

    Paik, P. K.; Fan, P. D.; Qeriqi, B.; Namakydoust, A.; Daly, B.; Ahn, L.; Kim, R.; Plodkowski, A.; Ni, A.; Chang, J.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Brief report: Combination of osimertinib and dacomitinib to mitigate primary and acquired resistance in EGFR-mutant lung adenocarcinomas
    Journal Article

    Elkrief, A.; Makhnin, A.; Moses, K. A.; Ahn, L. S.; Preeshagul, I. R.; Iqbal, A. N.; Hayes, S. A.; Plodkowski, A. J.; Paik, P. K.; Ladanyi, M.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas
    Journal Article

    Paik, P. K.; Luo, J.; Ai, N.; Kim, R.; Ahn, L.; Biswas, A.; Coker, C.; Ma, W.; Wong, P.; Buonocore, D. J.; more...
    Nature Communications (2022)

    Fulltext@MSK | Save
  • Tepotinib: Management of adverse events in patients with MET exon 14 skipping non-small cell lung cancer
    Review

    Ahn, L.; Alexander, T.; Vlassak, S.; Berghoff, K.; Lemmens, L.
    Clinical Journal of Oncology Nursing (2022)

    Fulltext@MSK | Save
  • Phase 1 clinical trial of trametinib and ponatinib in patients with NSCLC harboring KRAS mutations
    Journal Article

    Arbour, K. C.; Manchado, E.; Bott, M. J.; Ahn, L.; Tobi, Y.; Ni, A. A.; Yu, H. A.; Shannon, A.; Ladanyi, M.; Perron, V.; more...
    JTO Clinical and Research Reports (2022)

    Fulltext@MSK | Save
  • Erlotinib and trametinib in patients with EGFR-mutant lung adenocarcinoma and acquired resistance to a prior tyrosine kinase inhibitor
    Journal Article

    Luo, J.; Makhnin, A.; Tobi, Y.; Ahn, L.; Hayes, S. A.; Iqbal, A.; Ng, K.; Arcila, M. E.; Riely, G. J.; Kris, M. G.; more...
    JCO Precision Oncology (2021)

    Fulltext@MSK | Save
  • Managing side effects of tepotinib treatment to optimize outcomes for patients with non-small cell lung cancer harboring MET exon 14 skipping: Expert guidance based on clinical experience
    Meeting Abstract

    Alexander, T.; Ahn, L.; Berghoff, K.; Vlassak, S.; Lemmens, L.
    Oncology Nursing Forum (2021)

    Fulltext@MSK | Save
  • Phase II study of TAK228 in patients with advanced non-small cell lung cancer (NSCLC) harboring NFE2L2 and KEAP1 mutations
    Meeting Abstract

    Paik, P. K.; Ahn, L. S. H.; Plodkowski, A. J.; Fan, P. D.; Rudin, C. M.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save